版本:
中国

BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs

Oct 17 Regeneron Pharmaceuticals Inc

* Regeneron and Teva provide update on fasinumab clinical development programs

* Regeneron Pharmaceuticals Inc - FDA has placed phase 2B study in chronic low back pain on clinical hold

* Regeneron - FDA requested amendment of study protocol after observing case of adjudicated arthropathy in a patient receiving high dose fasinumab

* Regeneron- A separate agreement with co , Mitsubishi Tanabe Pharma has exclusive development, commercial rights to fasinumab in Japan, Korea ,9 countries Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐